Eli Lilly is investing $5.3 billion to expand their Lebanon, Indiana site in order to increase production of the metabolic disorder drugs Zepbound and Mounjaro, both of which contain the active pharmaceutical ingredient tirzepatide. The expansion, set to be operational by late 2026, will create 200 additional jobs and bring Lilly’s total investment in the site to $9 billion. Indiana is providing economic incentives for the project, which is part of Lilly’s larger manufacturing investments totaling over $18 billion. The company also has manufacturing facilities in North Carolina, Ireland, Germany, and Wisconsin, with plans to continue expanding.
Source link
Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro
